Melanie Gloria has been appointed as Acelyrin Inc.’s chief operating officer and will oversee the biopharmaceutical company’s business operations.

Acelyrin is based in Woodland Hills and develops therapeutics.
Gloria was the senior vice president of development operations at Horizon Therapeutics prior to joining Acleyrin. She is a former oncology nurse and has 20 years of experience in biotechnology developed through leading multiple research and development functions.


Gloria has also worked with and led teams at biopharma company AbbVie and medical device company Abbott Laboratories.


“Her business operations, health care, and leadership experience will benefit Acelyrin and our patients as we pursue our vision of bringing life-changing therapies to those with serious diseases,” Dr. Shao-Lee Lin, Acelyrin’s co-founder and chief executive, said in a statement.


The appointment comes not long after Acelyrin secured $250 million in Series B funding and a licensing agreement with Affibody AB in November.


Gloria has received multiple health care awards and serves on the board of Lake County Haven, a social service agency that helps homeless women and their children access independent living conditions.


“I am thrilled to join Acelyrin and this team of passionate colleagues as we work together to change patients’ lives with innovative drug therapies,” Gloria said in a statement.